Skip to main content
. 2017 Jul 27;8(65):108548–108555. doi: 10.18632/oncotarget.19625

Figure 2. Subgroup Kaplan-Meier analyses of overall survival to assess prognostic value of STMN1 in GBC patients.

Figure 2

(A) all patients. (B) patients with TNM III- IV stage tumor. (C) patients with N0 stage tumor. (D) patients with G3-4 differentiated tumor. (E) and (F) ROC analysis of the prognosis sensitivity and specificity for overall survival by TNM stage model and TNM stage/STMN1 expression model in all patients at 12 months and 36 months, respectively.